Compare · LAB vs RVTY
LAB vs RVTY
Side-by-side comparison of Standard BioTools Inc. (LAB) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LAB and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $10.97B, about 24.4x LAB ($448.9M).
- Over the past year, LAB is down 21.8% and RVTY is up 9.0% - RVTY leads by 30.8 points.
- LAB has been more active in the news (10 items in the past 4 weeks vs 2 for RVTY).
- RVTY has more recent analyst coverage (19 ratings vs 5 for LAB).
- Company
- Standard BioTools Inc.
- Revvity Inc.
- Price
- $0.85-25.90%
- $101.24+2.84%
- Market cap
- $448.9M
- $10.97B
- 1M return
- -15.58%
- +2.40%
- 1Y return
- -21.81%
- +9.01%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2011
- News (4w)
- 10
- 2
- Recent ratings
- 5
- 19
Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Latest LAB
- SEC Form 425 filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Standard BioTools and Treeline Biosciences Announce Merger Agreement
- SEC Form 8-K filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Leadership Update
- SEC Form SD filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Financial Officer Kim Hanjoon Alex covered exercise/tax liability with 18,871 shares, decreasing direct ownership by 0.68% to 2,760,530 units (SEC Form 4) (tax liability)
- SVP & Chief Business Officer Mackay Sean covered exercise/tax liability with 25,729 shares, decreasing direct ownership by 2% to 1,006,552 units (SEC Form 4) to satisfy tax liability
- President & CEO Egholm Michael covered exercise/tax liability with 97,626 shares, decreasing direct ownership by 1% to 6,597,956 units (SEC Form 4) (for withholding tax)
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)